NCT03728335View on ClinicalTrials.gov

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

January 11, 2027

Study Completion Date

January 11, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Enasidenib Mesylate

Given PO

Trial Locations (2)

33612

SUSPENDED

Moffitt Cancer Center, Tampa

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER